MEDication Focused Outpatient Care for Underutilization of Secondary Prevention

This project conducted a multicenter, cluster-randomized study utilizing a centralized CVRS
for medical offices with large geographic, racial and ethnic diversity to determine the
extent to which the CVRS model will be implemented. Twenty primary care offices were
randomized to either the CVRS arm or a usual care arm, and 18 continued in the study. Each
clinic enrolled 20-30 patients per office for a total of 402 subjects, of which 186
represented racial minorities.

Subjects in the intervention arm clinic had regular contact by phone, email or text with a
CVRS clinical pharmacist housed at the University of Iowa. The pharmacist communicated with
the subject, with the site clinical pharmacist and, as needed, with the site provider to
optimize both the subject's pharmaceutical regimen and lifestyle behaviors. The CVRS
intervention lasted for 12 months.

A complex algorithm was used to calculate the degree to which the subject's care and medical
regimen follows national guidelines for reducing the risk of developing cardiovascular risk.

Post-intervention telephone interviews are being conducted with 20 intervention subjects in
order to assess their experience with the intervention and barriers and facilitators to the
intervention.

Inclusion Criteria:

- English speakers age 55 or greater

- Must have a medical history of at least one of the following:

- Coronary artery disease

- Myocardial infarction

- Stroke

- Transient Ischemic Attack

- Atrial Fibrillation

- Systolic heart failure

- Peripheral vascular disease/claudication

- Carotid artery disease

- Diabetes with either: Low density lipoprotein (LDL) 100 or greater AND/OR systolic
blood pressure 140 or higher or diastolic blood pressure 90 or higher

Exclusion Criteria:

- Signs of acute angina, stroke, heart failure or renal failure

- Systolic blood pressure 200 or greater or diastolic blood pressure 115 or greater

- Significant hepatic disease, including: Cirrhosis, Hepatitis B or C infection, Alanine
Aminotransferase (ALT) or Aspartate Aminotransferase (AST) 3 times control or higher,
or total bilirubin 2.0 mg/dl or higher